Johnson & Johnson Announces Quarterly Dividend of $0.95 (NYSE:JNJ)

Share on StockTwits

Johnson & Johnson (NYSE:JNJ) announced a quarterly dividend on Monday, July 15th, RTT News reports. Stockholders of record on Tuesday, August 27th will be given a dividend of 0.95 per share on Tuesday, September 10th. This represents a $3.80 annualized dividend and a dividend yield of 2.98%. The ex-dividend date is Monday, August 26th.

Johnson & Johnson has raised its dividend payment by an average of 6.3% annually over the last three years and has raised its dividend every year for the last 56 years. Johnson & Johnson has a dividend payout ratio of 46.7% indicating that its dividend is sufficiently covered by earnings. Analysts expect Johnson & Johnson to earn $9.09 per share next year, which means the company should continue to be able to cover its $3.80 annual dividend with an expected future payout ratio of 41.8%.

JNJ opened at $127.73 on Friday. Johnson & Johnson has a one year low of $121.00 and a one year high of $148.99. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.33 and a quick ratio of 1.04. The company’s 50 day simple moving average is $132.65 and its 200-day simple moving average is $136.53. The stock has a market capitalization of $346.44 billion, a P/E ratio of 15.61, a price-to-earnings-growth ratio of 2.22 and a beta of 0.69.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, July 16th. The company reported $2.58 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.42 by $0.16. Johnson & Johnson had a net margin of 20.08% and a return on equity of 38.63%. The business had revenue of $20.56 billion for the quarter, compared to analysts’ expectations of $20.39 billion. During the same period in the prior year, the firm earned $2.10 earnings per share. Johnson & Johnson’s revenue was down 1.3% compared to the same quarter last year. As a group, analysts anticipate that Johnson & Johnson will post 8.6 EPS for the current year.

In other Johnson & Johnson news, Director Marillyn A. Hewson acquired 3,000 shares of Johnson & Johnson stock in a transaction on Tuesday, June 11th. The shares were purchased at an average cost of $139.68 per share, with a total value of $419,040.00. Following the completion of the purchase, the director now owns 3,000 shares in the company, valued at $419,040. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.23% of the stock is currently owned by company insiders.

A number of brokerages have issued reports on JNJ. Credit Suisse Group set a $156.00 price objective on shares of Johnson & Johnson and gave the company a “buy” rating in a research note on Thursday, July 18th. Zacks Investment Research cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating and set a $139.00 price objective on the stock. in a research note on Thursday, July 18th. Barclays began coverage on shares of Johnson & Johnson in a research note on Friday, June 21st. They issued a “hold” rating and a $140.00 price objective on the stock. Goldman Sachs Group began coverage on shares of Johnson & Johnson in a research note on Tuesday, May 28th. They issued a “buy” rating on the stock. Finally, Raymond James reduced their price objective on shares of Johnson & Johnson from $147.00 to $146.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 17th. Five analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $148.56.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: Why is the price target of stocks important?

Dividend History for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.